SCHEMBL5146178

SCHEMBL5146178

CCCCC1=C(OC)C(=O)C(C)=C(CO)C1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
ALDH1A1 P00352 1/20 0.64
THRB P10828 1/20 0.64
LMNA P02545 1/20 0.58
PGR P06401 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
MAOA P21397 1/20 0.58
TBXA2R P21731 1/20 0.58
MAPK1 P28482 1/20 0.58
AVPR2 P30518 1/20 0.58
CYP2C19 P33261 1/20 0.58
HTR2B P41595 1/20 0.58
HTT P42858 1/20 0.58
PDE3A Q14432 1/20 0.58
SIRT2 Q8IXJ6 1/20 0.58
SLC29A1 Q99808 1/20 0.58
ALOX5 P09917 18/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14407319 0.87 MAPT (0.68) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL14459552 0.84 ALDH1A1 (0.64) MAPTTDP1ALDH1A1THRBALOX5
SCHEMBL5143424 0.84 MAPT (0.64) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL5141777 0.83 MAPT (0.51) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL17123724 0.81 MAPT (0.75) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL14407312 0.81 MAPT (0.56) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL16465116 0.80 MAPT (0.78) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL9578617 0.80 MAPT (0.58) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL16464673 0.80 MAPT (0.78) MAPTTDP1ALDH1A1THRBLMNA
SCHEMBL11857681 0.80 MAPT (0.96) MAPTTDP1ALDH1A1THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-09-06 US disclosed
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-30 US disclosed
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-30 US disclosed
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-30 US disclosed
WO-2007095630-A2 NEW UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
WO-2007095630-A2 NEW UBIQUINONE ANALOGS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed
WO-2007095631-A2 NEW DRUG DELIVERY SYSTEM FOR CROSSING THE BLOOD BRAIN BARRIER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208086-A1 UBIQUINONE ANALOGS AND METHODS OF USE NDUFB7, NDUFB1, NDUFB3 MAPT 4254/4885TDP1 1036/4885ALDH1A1 638/4885
US-20070203080-A1 New Drug Delivery System for Crossing the Blood Brain Barrier NDUFB5, NDUFB7, NDUFB3 MAPT 1404/4885TDP1 2726/4885ALDH1A1 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.